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ABSTRACT 
Two natural products, spiroxin A (isolated from a marine-derived fungal strain LL-
37H248) and angelmarin (isolated from the Japanese medicinal plant Angelica pubescens), have 
exhibited promising antitumor and antibacterial activities. Recent efforts in our laboratory have 
identified a precursor to spiroxin A, (S)-34, and a coumarin-based angelmarin derivative 50 as 
lead pharmacophores against human pancreatic adenocarcinoma cell line PANC-1. Both 
compounds induced PANC-1 cell death exclusively under nutrient-deprived conditions. The 
research presented herein includes an ongoing structure-activity relationship study based on (S)-
34 and an investigation of the correlation between cell culture medium components and the 
cytotoxicity of 50. For the former, current results showed no substantial effects of the absolute 
stereochemistry or the protecting group center of (S)-34 on its preferential cytotoxicity, 
suggesting that hydrophobicity may play an important role in the observed antitumor activity. In 
addition, the activity of compound 50 was enhanced in the absence of a combination of serum 
and glucose, which indicates a possible mechanism of action of 50 related to the inhibition of 
autophagy in PANC-1 cells.  
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INTRODUCTION 
Natural Products in Medicinal Chemistry 
For millennia, nature has provided mankind with the necessities to survive and thrive, 
including our largest medicine cabinet. Living organisms have been a source of medicinal 
products used for a myriad of diseases. The earliest record of using natural sources to treat 
illnesses can be dated back to around 2600 BC, documenting approximately 1000 plant species 
in Mesopotamia.1 Until the advent of modern pharmaceuticals, the treatment of diseases largely 
relied on plant concoctions and plant extracts. For example, willow bark extract was used to 
reduce fever and relieve pain in 400 BC. However, the active ingredient of willow bark was not 
identified until the 19th century, when salicylic acid (1, Figure 1), an early example of a 
physiologically active natural product, was discovered to be responsible for the medicinal 
properties of the extract. Even in modern times, natural products, which are isolated from living 
organisms, have played an essential role in medicinal chemistry. In the last 30 years, 64% of new 
drugs originated from natural products. For anticancer treatment in particular, about 80% of 
therapies were natural products per se or resembled natural products, highlighting their 
importance in contemporary drug discovery and development.2  
 
Figure 1. Structures of salicylic acid and aspirin 
However, reliance on solely natural sources poses problems for large-scale drug 






Salicylic Acid (1) Aspirin (2)
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products from their natural sources.   Thanks to the development of modern synthetic techniques, 
organic chemists are able to synthesize natural products in their laboratories. In fact, syntheses of 
natural products often yield analogs that offer improved medicinal properties than their natural 
precursors. For example, salicylic acid was optimized into aspirin (2, Figure 1), a common and 
effective pain reliever.  Another example is the discovery of paclitaxel (Taxol®) from the bark of 
Pacific yew tree Taxus brevifolia.  Since the initial discovery, structural derivatives such as 
docetaxel, Abraxane® and cabazitaxel have been developed with improved pharmacological 
properties.  
Among numerous natural products that provide inspirations for drug discovery and 
development, spiroxin A (3, Figure 3) and angelmarin (40, Figure 7) have been the focus of our 
research, due to the diverse biological activities of both compounds, such as antitumor and 
antibacterial activities. Moreover, recent efforts in our laboratory have demonstrated that 
structural analogs of both natural products are cytotoxic to pancreatic cancer cells.3,4,5  
Pancreatic Cancer 
Pancreatic adenocarcinoma is one of the most lethal human cancers. It is the fourth 
leading cause of cancer-related deaths in the United States. The American Cancer Society has 
estimated that there will be 48,960 new cases and 40,560 deaths in 2015. Among all cancers, the 
5-year survival rate of pancreatic cancer has remained the only cancer survival rate that is still 
below 10%.6 Pancreatic cancer is known for its early metastasis and aggressive invasion of 
surrounding tissues. Due to the lack of early detection methods and the absence of easily-
recognizable symptoms, patients are usually diagnosed at late tumor stages without surgical 
therapy options.7 Between 2004 and 2010, over 80% of pancreatic cancer patients were 
diagnosed at the regional or distant stage, where the tumor had spread to a different part of the 
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body or metastasized. Even for patients who were diagnosed at an early stage (or the localized 
stage), the 5-year relative survival rate was less than 30% (Figure 2).  Only 15% – 20% of all 
patients receive radiotherapy, among whom only 3% – 4% can achieve long-term cure.8 In 
addition, pancreatic cancer is highly resistant to conventional chemotherapies such as 
gemcitabine, Taxol®, 5-fluorouracil and cisplatin.9 Unfortunately, no effective clinical treatment 
is currently available to guarantee the complete eradication of pancreatic cancer.  
 
Figure 2. Percent of cases and 5-year relative survival by stage at diagnosis for pancreatic 
cancer.10 Figure taken from http://seer.cancer.gov/statfacts/html/pancreas.html. 
 
Throughout carcinogenesis, tumor cells are exposed to hypoxia and poor nutrient 
conditions, because of insufficient vascularization. Metabolic stress triggers angiogenesis – the 
creation of new blood vessels, which eventually results in tumor progression. Anti-angiogenesis 
to prevent tumor growth used to be considered the most promising anticancer therapy.11 
However, the role of angiogenesis in pancreatic cancer remains controversial, since pancreatic 
cancer is mostly hypovascular.12 Recently, angiogenesis inhibitors were reported ineffective in 
treating patients with pancreatic cancer.13 In 2000, Izuishi and coworkers proposed that 
pancreatic cancer cells might have acquired tolerance to nutrient deprivation throughout tumor 
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progression. In their study, pancreatic cancer cells and normal human fibroblasts were cultured 
in nutrient-deprived media lacking glucose, amino acids and serum. Four pancreatic cancer cell 
lines, including PANC-1, AsPC-1, BxPC-1, and KP-3, survived for 48 h under nutrient 
deficiency, whereas normal fibroblasts died within 24 h under the same conditions.11 Since 
normal tissues seldom encounter nutrient deprivation, the austerity of pancreatic cancer cells has 
become a novel biochemical target for cancer therapies. Since then, significant effort has been 
carried out to search for anti-austerity agents.  
Discovery and Synthetic History of the Spiroxins 
In 1999, a marine-derived fungal strain LL-37H248 was collected from a soft orange 
coral in Vancouver Island, Canada. Bioassay-directed purification of the marine fungus yielded 
spiroxins A-E (3-7, Figure 3). As members of the bisnaphthospiroketal family, the spiroxins 
display intriguing structural features – two partially saturated naphthalene rings are connected 
via a spiroketal and a carbon-carbon (C-C) linkage. The saturated portion of each naphthalene 
unit, combined with an epoxide, creates a unique octacyclic ring system.14 Aside from the 
intricate ring systems, the spiroxins contain six stereogenic centers in a 20-carbon framework. In 
fact, the absolute stereochemistry of spiroxins A-E (3-7, Figure 3) was not confirmed until 
2001.15   
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Figure 3. Structures of spiroxins A-E. 
The complex structures of the spiroxins have made them challenging synthetic targets. To 
date, only one total synthesis has been published for all five spiroxins. In 2003, Miyashita and 
coworkers reported the total synthesis of (±)-spiroxin C via a Suzuki-Miyaura cross-coupling key 
step activated by tetra-n-butylammonium fluoride (TBAF). The simplified synthetic scheme is 
shown below (Scheme 1). The two naphthalene units 12 and 13 were prepared individually from 
known compounds (8-11). The key step of the synthesis (blue, Scheme 1) was to bring together 
the naphthalene units 12 and 13 to create a binaphthyl derivative 14 with two oxygen 
substituents at both peri-positions, which was achieved via a Pd(0)-catalyzed cross-coupling with 
the addition of TBAF. The binaphthyl derivative 14 was not only a key intermediate in the 
synthetic scheme, but it also served as a chiral auxiliary to direct the desired orientation of the 
basic bisnaphthospiroketal skeleton 17. Introduction of epoxides from a sterically less hindered 
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Scheme 1. Simplified total synthesis of (±)-spiroxin C. The key Suzuki-Miyaura cross-coupling 
step is highlighted in blue.16 
 
However, since the total synthesis of (±)-spiroxin C, only a few attempts have been 
reported en route to resolving the synthetic challenges posed by the complex structures of the 
spiroxins, including the work by Nabatame and coworkers. A hexacyclic spiroxin framework 27 
was constructed in a ten-step synthesis (Scheme 2), involving key steps such as CuCl-mediated 
oxidative biaryl coupling from 20 to 21 (blue, Scheme 2), oxidative desymmetrization from 22 to 
23 (green, Scheme 2), site-selective acetoxylation from 24 to 25 (pink, Scheme 2), and oxidative 
cyclization of 26 to the hexacycle 27 (purple, Scheme 2).17 Needless to say, the highly 
oxygenated and strained fused-ring system that all spiroxins share remains a challenging 
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Scheme 2. A ten-step synthesis of a hexacyclic spiroxin framework 27. Key steps are colored in 
blue, green, pink and purple.17 
 
Medicinal Significance of Spiroxin A 
Among all five spiroxins, only spiroxin A has been thoroughly investigated and found to 
possess biological activities. Spiroxin A was reported to show antitumor activity in nude mice 
against ovarian carcinoma (59% inhibition after 21 days, 1 mg/kg/dose), and exhibit cytotoxicity 
against a panel of 25 diverse cell lines with a mean IC50 value of 0.09 µg/mL. In evaluation of 
the mechanism of action, it was observed that spiroxin A caused a concentration-dependent 
nicking of pBR322 DNA, indicating that the cytotoxicity of spiroxin A might be partly exerted 
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have chemically-similar behaviors as quinone epoxides (see Figure 4 for examples of quinone 
epoxides), which can induce cell death via a variety of mechanisms such as DNA modification, 
alkylation or oxidation of essential protein thiol groups.18 Liquid chromatography and mass 
spectrometry (LC-MS) experiments in this study have demonstrated that spiroxin A formed 
conjugates when reacting with 2-mercaptoethanol 30 or dithiothreitol 31 (Figure 5).14 Thus, the 
exact mechanism of the cytotoxicity of spiroxin A might be more complicated and require a 
more thorough investigation. Spiroxin A also showed antibacterial activity against Gram-positive 
bacteria.14 To date, the biological activities of spiroxins B-E have not been reported.  
 
Figure 4. Examples of quinone epoxides. 
 
Figure 5. Structures of 2-mercaptoethanol 30 and dithiothreitol 31. 
 
Synthesis of the Core Structure of Spiroxin A 
Motivated by the potential therapeutic effects of spiroxin A, our laboratory sought to 
develop synthetic techniques that could achieve the enantioselective total synthesis of spiroxin 
A. In 2011, our laboratory reported a novel catalytic asymmetric approach (Scheme 3) to the 
core structure of spiroxin A, a tertiary naphthoquinol (S)-39, via a tandem oxidation/ring-opening 
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protection of (S)-33 was accomplished using tert-butyldiphenylsilyl chloride (TBDPSCl) and 
imidazole. Following the generation of a bromide intermediate (S)-35, the vinylarene (S)-36 was 
obtained via a Stille cross-coupling using trimethyl(phenyl)stannane. Deprotection of (S)-36 with 
TBAF produced the alcohol (S)-37. A directed m-CPBA epoxidation of (S)-37 generated the 
epoxyalcohol (S)-38. An oxidation/ring-opening of (S)-38 under Swern conditions afforded the 
desired chiral tertiary naphthoquinol (S)-39 (Scheme 3). Compared to the existing methods of 
preparing chiral tertiary naphthoquinols, the synthesis proposed by our group was less 
synthetically demanding in that there was no need for a chiral auxiliary, and thus it will be more 
flexible and convenient to construct other substituted tertiary chiral quinols. This approach also 
represented the first catalytic asymmetric entry to chiral tertiary naphthoquinols.19  
 
Scheme 3. Synthesis of enantioenriched tertiary naphthoquinol (S)-39. 
 
Inspired by the antitumor activity of spiroxin A and with ready access to the synthetic 
intermediates, we have decided to investigate which structural components of spiroxin A could 
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Structure-Activity Relationship (SAR) Study  
As a major paradigm in pharmacology, SAR studies examine the relationship between 
the molecular structures and all types of biological activities of chemical compounds. The 
fundamental assumption behind SAR studies is that the structure of the compound implicitly 
determines its biological properties. While developing SAR studies, scientists hope to not only 
pinpoint the structural components relevant to the activity, but also utilize the relationship to 
design compounds with enhanced biological properties. Residing at the intersection of chemistry, 
biology and statistics, SAR studies often require a multidisciplinary understanding of the project 
(Figure 6). A well-established SAR model generally consists of elements such as chemicals of 
interest, biological activities obtained via experimental/computational techniques, and chemical 
descriptors or attributes that may help rationalize the connection between structure and activity. 
Last but not least, researchers ought to exploit appropriate methods of analysis to reach plausible 
conclusions. Applications of SAR studies can also be found in chemical industries, 
environmental sciences and toxicology.20 
 
Figure 6. SAR at the intersection of chemistry, biology and statistics.20 Figure taken from 
McKinney et al., 2000. 
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Discovery of Angelmarin  
In 2006, a coumarin-based natural product, angelmarin (40, Figure 7), was isolated from 
the root of the Japanese medicinal plant, Angelica pubescens. The 23-carbon structure contains a 
columbianetin (41, Figure 7) core and a p-hydroxycinnamoyl group (blue, Figure 7) connected 
via an ester linkage. Circular dichroism spectrum of angelmarin revealed a clockwise spatial 
orientation of the two chromophores. Angelmarin was found to exhibit cytotoxicity against 
human pancreatic adenocarcinoma cell line PANC-1 preferentially under nutrient-deprived 
conditions. A concentration of 0.01 µg/mL induced 100% cell death within 24 h of starvation, 
and the cytotoxicity was more pronounced when the concentration of angelmarin was increased 
to 10 µg/mL, at which 100% cell death was observed within 6 h. Interestingly, the building 
blocks of angelmarin, columbianetin and p-hydroxycinnamic acid (42, Figure 7) were both 
inactive in nutrient-rich and nutrient-deprived conditions at even 100 µg/mL, indicating the 
importance of the unique structure of angelmarin.21  
 
Figure 7. Structures of angelmarin, columbianetin and p-hydroxycinnamic acid. 
Novel Isoprenylated Coumarins and their Antitumor Activity 
As the basic structure of angelmarin, coumarins (43, Figure 8) are ubiquitous in a number 
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activities such as anticancer, anti-viral, antifungal, anti-inflammatory, antioxidant, anticoagulant, 
antibacterial, antitubercular, and analgesic activities. In particular, hydroxycoumarin derivatives 
have been shown to exhibit promising antitumor, anti-flammatory and anti-viral effects.3 
Intrigued by the selective cytotoxicity of angelmarin and the frequent occurrence of coumarins in 
natural compounds, our laboratory launched SAR studies based on the core coumarin structure of 
angelmarin.  
 
Figure 8. Structure of coumarin with labeled positions and structure of a geranylgeranylated 
coumarin derivative 44. 
In 2011, our group reported a novel geranylgeranylated ether coumarin derivative (44, 
Figure 8) that was found to induce PANC-1 cell death at a concentration of 6.25 µM within 24 h, 
with preferential cytotoxicity under nutrient-deprived conditions.3 Since then, a library of 
isoprenylated coumarin derivatives (Table 1), consisting of three series of isoprenylated 
coumarin ethers with systematic variations in tail length (5, 10 or 15 carbons) and substitution 
position on the coumarin scaffold  (at 3-, 6- or 7-position) has been completed. The preparation 
of these ether compounds was achieved via a Williamson-ether synthesis using an isoprenyl 
bromide and an alkoxycoumarin anion pre-generated by treating the corresponding 

























































Table 1. In vitro cytotoxicity of compounds 45-53 against PANC-1 under nutrient-deprived 
(ND) and nutrient-rich (NR) conditions. Series 1, 2 and 3 differ by substitution position of the 
isoprenylated tail. LC50 values are obtained from Jun et al., 2014.4  
 
 
Scheme 4. General synthetic approach to isoprenylated coumarin derivatives.4 
The entire series was tested in vitro against PANC-1 cells. The survival of PANC-1 cells 
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farnesylated ether 50 at position 6 displayed the greatest cytotoxicity under nutrient-deprived 
conditions with an LC50 value as low as 4 µM. All compounds in this series were inactive under 
nutrient-rich conditions.4 To better understand the preferential cytotoxicity of the coumarin 
derivatives, we have chosen to probe the cellular mechanism of action of compound 50 because 
of its highest potency. To start off, we will investigate the effect of medium components on the 
cytotoxic activity of 50.  
Introduction to Investigation 
The research presented herein will be comprised of three parts, first, to validate the 
preliminary results obtained from a previous investigation, which suggested (S)-34 as a potential 
lead pharmacophore, second, to introduce an ongoing SAR study based on the structure of (S)-
34, and last but not least, to report the results pertinent to our investigation of medium 
components and the mechanism of antitumor activity of 50.  
1. Validation of Initial Lead Structure 
As previously described, pancreatic tumor cells are known to be significantly more 
resistant than normal human cells under nutrient-deprived conditions.11 Therefore, an ideal 
selective anti-austerity agent should induce cell death only under nutrient-deprived conditions 
conferred by the absence of amino acids, glucose, and serum. A previous member of our 
laboratory had obtained preliminary data regarding the cytotoxicity of the four synthetic 
intermediates (S)-33, (S)-34, (S)-36 and (S)-37 (Scheme 3). In her study, (S)-34 was found to be 
the only compound that demonstrated a preferential cytotoxicity under nutrient-deprived 
conditions, whereas no PANC-1 cell death was observed under nutrient-rich conditions, 
suggesting the potential of (S)-34 to become a lead structure of an SAR study. The other three 
intermediates (S)-33, (S)-36 and (S)-37 showed no activity in either medium.22 In order to 
	   20 
validate this exciting finding, more trials of in vitro cytotoxicity assays will be performed with 
the four synthetic intermediates, as well as the commercially-available epoxy ether 32, to 
complete the initial search for a lead structure. PANC-1 cells will be exposed to all five 
compounds under both nutrient-rich and nutrient-deprived conditions for 24 h. Cell survival rates 
will be reported as an indication of the cytotoxic activity of all compounds.  
2. SAR Study based on (S)-34 
Upon an examination of the structure of (S)-34, we have identified three places of 
immediate interest: the chiral carbon 1 (orange, Figure 9), the tert-butyldiphenylsilyl (TBDPS) 
protecting group (pink, Figure 9), and substituents on carbon 4 (purple, Figure 9).  
 
Figure 9. Expanded structure of (S)-34. 
Chirality plays an important role in myriad natural processes, especially in drug-protein 
interactions. Proteins are usually enantioselective towards their binding partners, and thus a 
specific stereochemistry is often required for a drug to effectively bind to its molecular target. 
Additionally, chirality in drug design is addressed in governmental regulations. In 1992, the 
United States Food and Drug Administration issued guidelines and policies regarding the 
development of chiral compounds23, emphasizing the importance of chirality in drug design.   
In our study, the enantiomer of (S)-34, (R)-34 as well as the racemic mixture, will be 
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of (R)-34 can be achieved via a two-step process shown in Scheme 5. The racemic mixture will 
be obtained by combining equal amounts of (S)-34 and (R)-34. Optical rotation measurements 
will be performed to confirm the chirality of each compound.  
 
Scheme 5. Two-step synthesis to prepare (R)-34. 
The significant difference in cytotoxicity between (S)-34 and (S)-33 indicated that the 
presence of the TBDPS protecting group might play a key role in the selective cytotoxicity 
observed for (S)-34. However, it was unclear whether the TBDPS group alone or the 
combination of the (S)-33 scaffold and the protecting group resulted in the cytotoxicity. 
Therefore, we are going to test the potency of tert-butyldiphenylsilanol (TBDPSOH) as well as a 
variety of protected (S)-33. TBDPSOH will be generated from a hydrolysis reaction of TBDPSCl 
under basic conditions (Scheme 6).  Protecting groups of interest include silyl protecting groups 
such as tert-butyldimethylsilyl (TBDMS) and trimethylsilyl (TMS). Both groups resemble 
TBDPS in that they are all silicon-containing protecting groups, but TBDMS and TMS are 
relatively less sterically hindered. In TBDMS, the two phenyl groups are replaced with methyl 
groups, whereas in TMS, all three bulky substituents are replaced with methyl groups. It will be 
interesting to see whether the size of the protecting group could cause any effect on the antitumor 
activity. Besides, several other protected (S)-33 with common alcohol protecting groups such as 
benzyl, tetrahydropyran (THP) and trityl, which do not contain silicon, will also be added to the 
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Scheme 6. Synthesis of TBDPSOH from commercially-available TBDPSCl. 
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The inactivity of (S)-36, which also contains a TBDPS protecting group, might provide 
some insight into whether hydrophobicity played a role in the activity observed in this series of 
compounds. To investigate the correlation between hydrophobicity and cytotoxicity, the octanol-
water partition coefficients of various compounds (LogP) will be calculated using 
ChemBioDraw® 13.0 (PerkinElmer, Cambridge, MA, USA). LogP is important for predicting 
cell membrane penetration24 and studies have utilized LogP values to estimate biological 
activities of structurally-related compounds. For example, Fratello et al. reported a good 
correlation between the cytotoxicity of halogenated benzenes and their LogP values25, whereas 
Sasaki and coworkers re-evaluated the tumor-specific cytotoxicity of mitomycin C, bleomycin 
and peplomycin based on the LogP values.26 Studies have shown an excellent correlation 
between ChemDraw® estimated ClogP values and experimentally-mesaured LogP values.24,27 
For example, the validity of in-silico predictions of LogP values was investigated in a recent 
study by Wolk et al. where a comparison was made between experimental and calculated 
partition coefficients of 154 drugs. In this study, CLogP estimations by ChemDraw® 8.0  
(PerkinElmer, Cambridge, MA, USA) and the experimental values demonstrated an excellent 
correlation (r2 = 0.97).27  
One method to alter the hydrophobicity of the lead structure (S)-34 is to modify the 
substituents on carbon 4 (purple, Figure 9). We have proposed to install a methyl group as an 
alternate substituent. This modification should in theory decrease the CLogP value of the 
resulting compound. Besides, by replacing the bulky phenyl group with a simple methyl group, 
we hope to also test if the steric hindrance at carbon 4 influences the cytotoxicity. The suggested 
modification can be achieved via an adjustment of reagents in the Stille cross-coupling, an 
intermediate step in Scheme 3. The proposed reaction is shown in Scheme 7. 
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Scheme 7. Synthesis of (S)-61 via a Stille cross-coupling reaction. 
3. Effect of Medium Components on Cytotoxicity of 50 
To investigate the effect of medium components on the cytotoxic activity of 50, we will 
prepare six media consisting of different nutrient combinations, a summary of which is shown in 
Table 3. PANC-1 cells will be cultured in the appropriate medium for 24 h prior to the exposure 
of 50. Similar studies on medium components have been performed with a variety of 
pharmaceutical compounds. For example, Izuishi and coworkers showed that troglitazone (62, 
Figure 10) inhibited PANC-1 cell survival under deprivation of both glucose and serum, whereas 
LY294002 (63, Figure 10) inhibited PANC-1 cell survival under deprivation of amino acids, 
irrespective of the presence of glucose or serum.11 Esumi et al. discovered that pyrvinium 
pamoate (64, Figure 10) was preferentially toxic when glucose was depleted, irrespective of the 
presence of serum or amino acids.28 Awale and coworkers reported cytotoxicity of arctigenin 
(65, Figure 10) at a concentration of 0.01 µg/mL under glucose-deprived conditions.29 While we 
seek to identify the key nutrient(s) that may activate the antitumor activity of 50, we decided to 
explore whether 50 exhibits universal cytotoxicity against other pancreatic cancer cell lines. 
Therefore, the cytotoxicity of 50 against two additional pancreatic cancer cell lines BxPc-3 and 
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Medium Number Glucose Amino Acid Serum 
1 + - - 
2 - + - 
3 - - + 
4 + + - 
5 + - + 
6 - + + 
Table 3. Six cell culture media prepared via addition of different combinations of nutrients to 
nutrient-deprived medium.  
 
































	   27 
RESULTS AND DISCUSSION 
Validation of Initial Lead Structure 
As previously described, pancreatic tumor cells are known to be significantly more robust 
than normal human cells under nutrient-deprived conditions.11 Therefore, an ideal selective anti-
austerity agent should induce cell death only under nutrient-deprived conditions conferred by the 
absence of amino acids, glucose, and serum. Replicate experiments were conducted for five 
compounds (32, (S)-33, (S)-34, (S)-36, (S)-37, Scheme 3) in vitro to evaluate their cytotoxicity 
against the human pancreatic adenocarcinoma cell line PANC-1 under both nutrient-rich and 
nutrient-deprived conditions. The goal of this study was to validate the preliminary results of 
compounds (S)-33, (S)-34, (S)-36 and (S)-37 obtained by a former lab member22, and identify a 
lead structure with the additional results for epoxy ether 32.  Survival of PANC-1 cells under 
nutrient-deprived and nutrient-rich conditions within 24 h following exposure to all five 
compounds is shown in Figure 11. We were pleased to discover that compound (S)-34 did indeed 
meet our expectation for an ideal anti-austerity agent: it exhibited preferential cytotoxicity under 
nutrient-deprived conditions with an LC50 value of 11 µM. Administration of 100 µM of (S)-34 
induced 88% cell death under nutrient-deprived conditions, whereas no cytotoxicity was 
observed under nutrient-rich conditions. Among the other compounds tested, compounds 32, (S)-
33 and (S)-36 showed no cytotoxicity in either medium condition, regardless of the concentration 
of the compound. Compound (S)-37 also did not show appreciable cytotoxicity. It induced 30% 
cell death only at 100 µM, exhibiting no cytotoxicity at low concentrations.5 The preferential 
cytotoxicity of (S)-34 enabled the identification of a useful pharmacophore, leading to an 
ongoing SAR study described in the next section.  
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Figure 11. Survival of PANC-1 cells under nutrient-deprived conditions (red) within 24 h. 
PANC-1 cell survival under nutrient-rich conditions (blue) was examined as control. (S)-34 
exhibited preferential cytotoxicity with an LC50 value of 11 µM. All cell viabilities are means of 
±SEM, n = 3. Concentrations of compounds investigated were 6.25, 12.5, 25, 50 and 100 µM. 
SAR Study based on (S)-34 
Based on the results reported in the previous section, we identified three attributes of (S)-
34 that might account for its preferential cytotoxicity, including the chirality of carbon 1 (orange, 
Figure 9), the TBDPS protecting group (pink, Figure 9), and the substituents on carbon 4 (purple, 
Figure 9).  The proposed structures of the SAR compound library are summarized in Table 2. 
This section will be divided into two parts: part I will focus on the synthesis of the SAR library 
and part II will present and discuss the biological evaluations of  (S)-34 analogs.  
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1. Preparation of the SAR Library 
Two-step Synthesis of (R)-34 – Asymmetric Ring Opening 
The preparation of (R)-34 involved a palladium-catalyzed reductive asymmetric ring 
opening from the cyclic ether 32 to a chiral homoallylic alcohol (R)-33, followed by the 
protection of the alcohol using TBDPSCl (Scheme 5). 
The palladium-catalyzed ring opening reaction was first reported by Li and coworkers30, 
as a convenient and mild method to stereoselectively prepare 1,2-dihydronaphth-1-ol in one pot 
from easily accessible starting materials. The reaction was accomplished in the presence of an 
organic carboxylic acid, zinc metal, and a palladium metal complex with a chiral bidentate ligand, 
all of which were necessary for a successful reaction.30 In our study, the conversion of 32 to (R)-
33 was achieved using valproic acid, zinc metal, and Pd[(S)-binap]Cl2 (Figure 12).  
 
 
Figure 12. Structures of valproic acid and Pd[(S)-binap]Cl2.                 
A test reaction of 100 mg was first performed following the same procedures described in 
the published work by our previous lab members.19 A first attempt of purification via Preparatory 
Thin Layer Chromatography (Prep TLC) was not sufficient to yield a pure desired product. The 
Hydrogen Nuclear Magnetic Resonance (1H-NMR) spectrum of the isolated product in acetone-
d6 contained additional signals between 0.5-2 ppm suggesting the presence of some 
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Figure 13. 1H-NMR spectrum of (R)-33 with contamination between 0.5-2 ppm. Integrations of 
peaks are shown above chemical shifts. 
The contamination was speculated to consist of mainly hydrocarbons due to the upfield position 
of the corresponding peaks. An 1H-NMR spectrum of the same compound was taken in benzene-
d6, and an increase of peak intensities within the same region was observed. Upon examination 
of participating reagents in the reaction mixture, the contamination was confirmed to be residual 
valproic acid (Figure 14), which contained shielded hydrogens that had NMR signals within 0.5-
2 ppm.  
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Figure 14. 1H-NMR spectra of the desired product (R)-33 in acetone-d6 (A) and benzene-d6 (B). 
There was an increase in peak intensity between 0.5-2 ppm.  
 
Additional extraction to remove the residual valproic acid and purification via Prep TLC were 
performed, reducing the amount of valproic acid in the product by 75% (Figure 15).  The 
characterization of (R)-33 was completed with 13C-NMR spectroscopy, High Resolution Mass 
Spectrometry (HRMS), and polarimetry. 13C-NMR and HRMS results were in good agreement 
with the structure, while the optical rotation (+42.9°) was slightly higher than the expected value 
(+39.3°), since (S)-33 has an optical rotation of -39.3°.19 The fully characterized (R)-33 was 
obtained in 18% yield. 
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Figure 15. 1H-NMR spectra of the desired product (R)-33 before (A) and after (B) additional 
purification. Impurity intensity decreased by 75%.  
 
 A second scale-up reaction of (R)-33 was conducted, followed by column 
chromatography for purification, which unfortunately did not yield a pure product. Residual 
valproic acid was detected in the initial 1H-NMR spectrum. Therefore, further purification via 
extraction and Prep TLC was required and performed prior to characterizing the product. In this 
reaction, (R)-33 demonstrated an optical rotation of +28.0° in 48% yield.  
 While the detailed pathway31 of the catalytic transformation was not clear, a general 
reaction mechanism was proposed based on the reaction conditions (Figure 16). Pd[(S)-
binap]Cl2, an 18-electron Pd(II) species, was first reduced to Pd(0) by zinc metal – a key step to 
initiate the catalytic cycle, which also explained why no reaction was observed in the absence of 
Zn. Oxidative addition of an organic acid, or valproic acid in this case, to Pd(0) led to the 
generation of Pd(II) hydride species (66, Figure 16), where the Pd metal coordinates with the 
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carbon-carbon double bond of 32 via the endo face. Insertion of the double bond to the Pd center 
generated the intermediate 67, followed by a β-heteroatom elimination to achieve the 
intermediate 68. Protonation of 68 yielded the desired product (R)-33 and regenerated the Pd(II) 
species 69, which could be reduced to Pd(0) by Zn metal to re-enter the catalytic cycle. The 
stereochemistry of the binaphthalene ligand in the Pd complex played a key role in facilitating 
the stereoselectivity of the reaction. In fact, when Pd[(R)-binap]Cl2 was used, the Pd metal 
coordinated the carbon-carbon double bond via the exo face, and subsequent β-elimination and 
protonation resulted in the deprotected lead structure (S)-33. Therefore, this Pd-catalyzed ring 
opening method allowed generation of either stereoisomer with high enantioselectivity under 
mild conditions.30  
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Figure 16. Proposed mechanism for Pd-catalyzed ring opening. 
Two-step Synthesis of (R)-34 – Protection of (R)-33 
 The protection of the homoallylic alcohol (R)-33 (Scheme 5) was accomplished using 
TBDPSCl, imidazole and DMAP to generate the TBDPS-protected silyl ether (R)-34 in 64% 
yield. The identity of (R)-34 was confirmed via 1H-NMR, 13C-NMR and HRMS, a representative 
of which with correctly assigned peaks is shown in Figure 17. (R)-34 showed an optical rotation 
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Figure 17. 1H-NMR spectrum of (R)-34 with assigned peak and corrected integrations. 
 
As common reagents in protection of alcohol, imidazole and DMAP facilitated the 
formation of intermediates in the SN2-like mechanism (Figure 18). DMAP first targeted the 
electrophilic silicon to generate a pyridinium cation 70, making silicon more susceptible to 
nucleophilic attack by alcohol (R)-33. Imidazole extracted a proton from the intermediate 71, 
generating the desire product (R)-34. 
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Figure 18. Mechanism of the protection reaction. 
Preparation of Racemic 34 
 The preparation of the racemic mixture of (R)- and (S)-34 was achieved by simply 
combining equal masses of each enantiomer. The resulting compound showed no optical 
rotation. The purity of 34 was briefly checked via TLC, where only one spot with the correct Rf 
value appeared.  
Synthesis of 55 via Hydrolysis of TBDPSCl (54) 
 Hydrolysis of TBDPSCl occurred under treatment with KOH, H2O and CH3OH (Scheme 
6). This reaction followed a basic SN1 mechanism, where TBDPS cation was created after the 
departure of the leaving group –Cl, and hydroxide anions performed the nucleophilic attack to 
install the hydroxyl group (Figure 19). Full characterization of 55 was completed with 1H-NMR, 
13C-NMR and HRMS. 1H-NMR spectra before and after D2O shake are shown in Figure 20. The 
intensity of the peak between 5-6 ppm (red, Figure 20) decreased while the peak intensity of 
water increased after the addition of D2O, which confirmed that the exchangeable proton 
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Figure 19. Mechanism of hydrolysis. 
 
 
Figure 20. 1H-NMR spectra of 55 before and after D2O shake. 
 It was discovered by accident that TBDPSCl hydrolyzed on silica gel. When TBDPSCl 
was loaded on a TLC plate, it interacted with the slightly acidic silica gel to produce the 
decomposition product TBDPSOH, which was fortunately the desired product. This hypothesis 
was proven by a 2D TLC experiment, where after a regular TLC experiment, the plate was 
turned 90° and let develop in the same solvent system. The decomposition product such as 
TBDPSOH (blue dot, Figure 21, left) would be stable and appear still as one spot, while the 
residual reactant such as TBDPSCl (red dot, Figure 21, left) would continue being hydrolyzed 
and appear as two spots, thus the final markings on the TLC plate should resemble those on plate 
C in Figure 21 (left). The resulting plate indeed demonstrated the expected pattern (Figure 21, 
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Figure 21. Schematic diagram of a 2D-TLC experiment (left) and the expected pattern was 
observed on the actual TLC plate (right).  
 
Synthesis of (S)-60 via Tritylation of (S)-33 
 Tritylation is another common method of protecting hydroxyl functional groups, and is 
usually conducted in a manner analogous to TBDPS protection reactions. (S)-60 was generated 
in 41% yield by treating (S)-33 with trityl chloride (TrtCl), DMAP and Et3N. Likewise, the 
reaction underwent an SN2-like mechanism where DMAP replaced imidazole and formed 
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Figure 22. Mechanism of tritylation. 
Synthesis of 75 via Hydrolysis of TBDMSCl (74) 
 
Scheme 8. Hydrolysis of TBDMSCl.  
 Prior to synthesizing other analogs of (S)-34, such as (S)-56 (Table 2), we decided to first 
add TBDMSOH (75) to our compound library, since it can be easily obtained from hydrolysis of 
TBDMSCl (74) under treatment with KOH, H2O and CH3OH (Scheme 8). This reaction 
followed the exact same mechanism as hydrolysis of TBDPSCl. Since neither 74 nor 75 was 
UV-active, no chromatography techniques were exploited in isolating the desired product. 
Characterization of 75 included 1H-NMR, 13C-NMR and GC/MS, and 75 was obtained in 33% 
yield.  
2. Biological Evaluations of SAR Analogs 
Cytotoxicity assays against PANC-1 cells were performed with compounds (R)-33, (R)-
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viability within 24 h upon treatment with different compounds is shown in Figure 23 and 25. The 
first attribute examined was the chirality of carbon 1 (orange, Figure 9). To our surprise, 
compound (R)-34 exhibited an even better cytotoxic activity than the lead enantiomer, with an 
LC50 value of 4 µM under nutrient-deprived conditions, about 64% lower than the LC50 of (S)-
345 (11 µM, Figure 11). The racemic compound 34 showed an LC50 value of 7 µM under the 
same conditions, which was approximately an average of the LC50 values of the enantiomers. 
However, both (R)-34 and racemic 34 showed modest cytotoxicity against PANC-1 under 
nutrient-rich conditions, which was not observed in the case of (S)-34. Approximately 10-20% 
cell death was observed for higher concentrations of (R)-34 and racemic 34 under nutrient-rich 
conditions, whereas (S)-34 was completely inactive under the same conditions. Additionally, (R)-
33 was found to be inactive in either medium condition, similar to the behavior of (S)-33 (Figure 
23). Therefore, chirality of carbon 1 (orange, Figure 9) did not seem to be responsible for the 
preferential cytotoxicity of the lead compound. Although (R)-34 and racemic 34 exhibited better 
potency inducing PANC-1 cell death, (S)-34 demonstrated more promising specificity toward 
tumor cells. Despite a likely trade-off between potency and tumor specificity in this series of 
compounds, a direct reductive epoxide ring-opening method to prepare a racemic combination of 
the homoallylic alcohol 33 may offer an alternative approach to SAR exploration, since absolute 
stereochemistry did not significantly impact the antitumor activity. This proposed reaction could 
be achieved with Pd catalysts32, LiH33 or boron catalysts34, which could greatly reduce the cost 
of reagents, as the chiral Pd complexes (Pd[(S)-binap]Cl2 and Pd[(R)-binap]Cl2) cost 
$139.00/gram35 and $806.00/gram36, respectively. Moreover, the symmetry of epoxy ether 32 
will also eliminate the concern of regioselectivity. 
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Figure 23. Survival of PANC-1 cells under nutrient-deprived conditions (red) and nutrient-rich 
conditions (blue) within 24 h. (R)-34 and racemic 34 showed preferential cytotoxicity with LC50 
values of 4 µM and 7 µM, respectively. All cell viabilities are means of ±SEM, n = 3. Replicate 
experiments were performed and similar values were obtained. Concentrations of compounds 
investigated were 6.25, 12.5, 25, 50 and 100 µM. 
 
 Next, we investigated the effect of protecting groups on the cytotoxic activity of (S)-34. 
Comparing (S)-34 to (S)-33, we hypothesized that the cytotoxicity of (S)-34 was a result of either 
the TBDPS- protecting group alone or the combination of the naphthalene scaffold and the 
protecting group. To test the first hypothesis, PANC-1 cells were treated with TBDPSOH, a 
hydrolysis product derived from TBDPSCl. Interestingly, TBDPSOH exhibited a preferential 
cytotoxicity against PANC-1 with an LC50 value of 48 µM (Figure 25), which was about four 
times higher than that of the lead structure. Thus, it is clear that the strong potency observed in 
(S)-34 required both the naphthalene unit and the protecting group. To continue our study, we 
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replaced the silicon-containing TBDPS group with a trityl group ((S)-60), which is composed of 
purely hydrogen and carbon atoms, in an effort to explore the impact of silicon on compound 
potency, while retaining similar steric hindrance posed by the protecting groups. In this case, the 
removal of silicon demonstrated a slight but not considerable reduction in both antitumor activity 
and anti-austerity. Compared to (S)-34, the tritylated alcohol (S)-60 exhibited less cytotoxicity 
against PANC-1 cells with an LC50 value of 19 µM, while losing the degree of specificity 
possessed by (S)-34. Less than 100% cell viability was seen under nutrient-rich conditions, with 
100 µM of (S)-60 inducing more than 30% cell death (Figure 25). Nonetheless, it is plausible to 
conclude from this study that the replacement of silicon with carbon seemed to exert a minor 
effect on the PANC-1 cell growth inhibitory activity. To account for the 8 µM difference 
between LC50 values of (S)-34 and (S)-60, we returned to examine the steric hindrance posed the 
TBDPS group and the trityl group. Although TBDPS and trityl groups both contain two phenyl 
substituents, TBDPS contains a t-butyl group as the third substituent, while the trityl group 
possesses a third phenyl ring (Figure 24).  Phenyl groups, because of their planar geometry, are 
generally less sterically demanding than t-butyl groups. Thus, we proposed that the small 
difference in the cytotoxic activities of (S)-34 and (S)-60 might be a result from the variation in 
sterics.  
 
Figure 24. Structures of TBDPS and trityl protecting groups. 
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protecting group, showed no cytotoxicity under either nutrient-deprived or nutrient-rich 
conditions (Figure 25). Recalling the moderate activity exhibited by TBDPSOH (55), we 
suspected hydrophobicity to be a key factor in explaining this set of results.  
 
Figure 25. Survival of PANC-1 cells under nutrient-deprived conditions (red) and nutrient-rich 
conditions (blue) within 24 h. 55 and (S)-60 showed preferential cytotoxicity with LC50 values of 
48 µM and 19 µM, respectively. (S)-60 also induced more than 30% cell death under nutrient-
rich conditions. All cell viabilities are means of ±SEM, n = 3. Replicate experiments were 
performed and similar values were obtained. Concentrations of compounds investigated were 
6.25, 12.5, 25, 50 and 100 µM. 
 
Hydrophobicity Calculations   
Given the observations mentioned previously and since hydrophobicity was initially 
included in the three attributes of interest, we performed LogP calculations using 
ChemBioDraw® 13.0 (PerkinElmer, Cambridge, MA, USA) for all compounds that have been 
biologically evaluated: 32, (S)-33 (also representing (R)-33), (S)-34 (also representing (R)-34 and 
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racemic 34), (S)-36 and (S)-37, 55, (S)-60 and 75 (Table 4). In the absence of the TBDPS 
protecting group, the ClogP values of compounds 32, (S)-33 and (S)-37, were relatively low 
compared to that of (S)-34, suggesting a possible correlation between increasing hydrophobicity 
and cytotoxicity. However, the TBDPS protected vinylarene (S)-36, possessing the highest 
ClogP value of 9.501, did not exhibit any cytotoxic activity. This suggested that even though an 
increase in hydrophobicity could be associated with cytotoxicity, an optimal range of 
hydrophobicity might be required to observe the desired activity. This idea was further tested 
with compounds 55, (S)-60 and 75. Table 4 displays an array of ClogP values ranging from 0 to 
10, where only compounds 55, (S)-60 and (S)-34 showed preferential cytotoxicity against 
PANC-1 cells. A possible optimal range of ClogP values seemed to occur between 4 and 8, 






Table 4. CLog(P) values of tested compounds. The values were obtained from ChemBioDraw® 
13.0. Compounds highlighted in red exhibited preferential cytotoxicity against PANC-1 cells.  
 
Effect of Medium Components on Cytotoxicity of 50 
The farnesylated ether 50 was prepared via a Williamson-ether synthesis between a 
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hydroxycoumarin with sodium hydride (Scheme 9).4  
 
Scheme 9. Synthesis of farnesylated ether 50. 
Our previous studies have shown that 50 exhibited selective cytotoxicity against PANC-1 cells 
under nutrient-deprived conditions, while no activity was observed under nutrient-rich 
conditions.4 Based on the different compositions of nutrient-rich and nutrient-deprived media, 
we hypothesized that lacking certain nutrients (a single nutrient or a combination of two) might 
account for the preferential cytotoxicity of 50. To identify the key nutrients, we prepared six cell 
culture media described in Table 3. Compound 50 was tested in vitro for its cytotoxic activity 
against PANC-1 cells under all six medium conditions, with nutrient-deprived and nutrient-rich 
media included as controls. The LC50 values and percent cell death at 100 µM of 50 are presented 
in Table 5. 
Medium Number Components LC50 (µM) Cell Death at 100 µM 
NDM Nutrient-Deprived 9 >100% 
2 NDM + AA 6 >100% 
4 NDM + AA + Glu 41 55% 
1 NDM + Glu >100 36% 
6 NDM + AA + Ser >100 24% 
3 NDM + Ser >100 18% 
5 NDM + Glu + Ser >100 13% 
NRM NDM + AA + Glu + Ser >100 19% 
 
Table 5. Effect of medium components on the preferential cytotoxicity of 50. Compound 50 
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In this study, the cytotoxicity was observed in the medium deprived of serum only, and in 
the medium deprived of a combination of serum and glucose, with LC50 values being 41 µM and 
6 µM, respectively. These initial results suggested that the lack of serum was linked to the 
observed cytotoxic activity, and that the lack of both serum and glucose resulted in maximum 
cell death when PANC-1 cells were exposed to 50. In all other medium conditions, compound 50 
showed no significant activity at 100 µM and displayed LC50 values greater than 100 µM. 
However, the fetal bovine serum (FBS) used to prepare all media described in Table 5 contained 
a relatively high concentration of glucose and amino acids. More definitive conclusions obtained 
from experiments conducted under media 6, 3 and 5 (Table 5) and NRM may require additional 
experiments replacing FBS with dialyzed serum to afford carefully controlled media conditions 
devoid of glucose and amino acids. Dialyzed serum, having a lower concentration of glucose and 
amino acids, is expected to more accurately assess the function of serum in the observed cell 
growth inhibitory activity of our compounds. Preliminary results from ongoing experiments37 are 
suggesting that the lack of glucose may also play a role in inhibiting PANC-1 cell proliferation 
under the treatment with 50.  
The cytotoxicity of 50 was also investigated in vitro against two other pancreatic cancer 
cell lines, BxPc-3 and Capan-2, in order to examine whether 50 possesses universal antitumor 
activities against pancreatic cancer. Survival of BxPc-3 and Capan-2 cells under nutrient-
deprived and nutrient-rich conditions within 24 h following the exposure to 50 is shown in 
Figure 26. 
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Figure 26. Survival of BxPc-3 and Capan-2 cells under nutrient-deprived conditions (red) and 
nutrient-rich conditions (blue) within 24 h. Compound 50 showed preferential cytotoxicity with 
LC50 values of 5 µM against both cell lines. All cell viabilities are means of ±SEM, n = 3. 
Replicate experiments were performed and similar values were obtained. Concentrations of 
compounds investigated were 6.25, 12.5, 25, 50 and 100 µM. 
 
Similar to PANC-1, both cell lines exhibited a preferential sensitivity to 50 only under 
nutrient-deprived conditions, with LC50 values of 5 µM against both cell lines (Table 6). LC50 
values were consistently greater than 100 µM under nutrient-rich conditions.  
 LC50 (µM) NDM LC50 (µM) NRM 
PANC-1 9 >100 
BxPc-3 5 >100 
Capan-2 5 >100 
 
Table 6. Preferential cytotoxicity of 50 against BxPc-3 and Capan-2. 
Deer and coworkers have reported several variances among pancreatic cancer cell lines. 
One feature that differentiates the three cell lines in our study is the expression of the inducible 
enzyme cyclooxygenase-2 (COX-2)38, which is often overexpressed in malignant tumors.39 
COX-2 promotes angiogenesis by converting arachidonic acid into bioactive molecules that will 
function as activating factors in angiogenesis.40 Moreover, selective COX-2 inhibitors enhance 
the curative effect of chemotherapies for pancreatic cancer.41, 42 As shown in Figure 27, BxPc-3 
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demonstrated the greatest level of COX-2, which was essentially undetectable in Capan-2 and 
PANC-1.38 However, since compound 50 exhibited a universal cytotoxicity against all three cell 
lines, the difference in the level of COX-2 might not be associated with the mechanism of action 
of 50.  
 
Figure 27. Western blot analysis for the basal expression of COX-2 in pancreatic cancer cell 
lines. Figure taken from Deer et al., 2010.38  
Future Directions 
Current results from the SAR study of spiroxin A precursors suggested small impacts of 
chirality and protecting group center on the preferential cytotoxicity of the lead compound. 
However, the sterics of the protecting group as well as the hydrophobicity of the entire structure 
seemed to play an more important role in explaining the observed antitumor activity of (S)-34. 
Therefore, we propose to further study these two attributes by expanding our current SAR 
compound library. Compounds (S)-78 and (S)-79 will be added to evaluate the steric hindrance 
posed by the protecting group, and alcohols 80, 81 and 82 will be included for hydrophobicity 
investigations (Table 7). Synthesis and biological evaluations of the updated SAR library will 
hopefully reveal the structural component(s) responsible for the antitumor activity of (S)-34, and 




Relative expression of COX-2 in PA cell lines. Basal expression of COX-2 was determined
by Western blot analysis in PA cell line lysates and quantified by densitometry. A:
Representative Western blot. All cell lines were acquired from the American Type Culture
Collection (ATCC, Manassas, VA) and propagated in ATCC recommended media. Cells
were grown to 80% confluence before preparation of cell lysates. Pr teins were sep rated by
SDS-polyacrylamide gel electrophoresis and transferred to PVDF membranes using standard
protocols. The membranes were probed with antibodies to COX-2 (mouse monoclonal,
Cayman Chemical, Ann Arbor, MI) and ȕ-actin (rabbit monoclonal, Cell Signaling
Technology, Danvers, MA) or GAPDH (mouse monoclonal, Novus Biologicals, Littleton,
CO) as total protein loading controls. B: Densitometric analyses. Autoradiographs of
Western blots were quantified using ImageJ software (National Institutes of Health,
http://rsb.info.nih.gov/ij/). COX-2 intensity was first normalized to the corresponding
loading control (ȕ-actin or GAPDH) and then normalized to the BxPC-3 ratio for each blot.
Data represents the combined results of four independent experiments (mean ± SEM).
Deer et al. Page 18






















































Protecting group center could be either 
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81 
 




Center could be either Si or C. 
 
Table 7. Updated SAR compound library.  
For the next stage of the medium component study, our goal is to explore the cytotoxic 
mechanism of action of compound 50 at a cellular level. We have initiated some early 
experiments focusing on nutrients that are essential for cell proliferation, the results of which 
have given rise to new studies to disclose the molecular target of compound 50. We have 
hypothesized that 50 might inhibit autophagy in PANC-1 cells. Autophagy is a catabolic 
mechanism that involves degradation of cellular constituents to maintain cellular energy levels, 
which is important for cells to respond to nutrient stress and survive nutrient starvation. 
Autophagy is also responsible for removing misfolded or aggregated proteins, clearing damaged 
organelles and eliminating intracellular pathogens.43,44 Current investigations are ongoing to test 
our hypothesis and hopefully determine whether such mechanism is valid, and if so, identify 
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CONCLUSION 
A spiroxin A precursor (S)-34 was confirmed to be a lead pharmacophore against human 
pancreatic cancer cell PANC-1, inducing 50% of PANC-1 cell death at 11 µM only under 
nutrient-deprived conditions, and 100% cell viability was observed under nutrient-rich 
conditions. The anti-austerity ability of the lead structure has led to an ongoing SAR study to 
examine the chirality of carbon 1 (orange, Figure 9) and the nature of the protecting group (pink, 
Figure 9) of  (S)-34. Compounds (R)-33, (R)-34, 34, 55, (S)-60 and 75 were prepared in 
sufficient yields with full characterization, and evaluated against PANC-1 cells.  We observed 
preferential cytotoxicity for compounds (R)-34, 34, 55 and (S)-60, three of which demonstrated 
less specificity toward nutrient starvation compared to (S)-34. Altering the absolute 
stereochemistry of carbon 1 (orange, Figure 9) or silicon center in the protecting group resulted 
in no dramatic changes in the cytotoxicity of the lead structure, whereas varying the 
hydrophobicity of the entire structure produced a wide spectrum of antitumor activities. In 
addition, we have included another aspect of the protecting group (steric hindrance) in the list of 
attributes under investigation. Future work will aim to complete the synthesis and evaluation of 
the updated SAR library, in order to identify pivotal structural components responsible for the 
preferential cytotoxicity. 
Investigating the effect of medium components on the cytotoxicity of 50 was our first 
step towards discovering the cellular mechanism of action of 50. In this study, deprivation of a 
combination of serum and glucose reproduced the cytotoxicity of 50 against PANC-1 cells seen 
under complete nutrient deprivation. A possible mechanism of action of 50 is the inhibition of 
autophagy in PANC-1 cells, but future efforts are required to obtain concrete evidence for this 
hypothesis.  
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EXPERIMENTAL 
General Protocol  
All reagents and solvents were purchased commercially from Sigma-Aldrich®, EMD, 
Acros Organics or TCI America and were used as they were received. All air- and moisture-
sensitive reactions were performed in oven-dried glassware, under nitrogen gas, as well as in 
anhydrous solvents.  Thin Layer Chromatography (TLC) was performed on pre-coated glass 
plates with silica gel 60 F254 purchased from VWR® to monitor reaction progress. Purification 
of desired products was accomplished via Preparatory Thin Layer Chromatography (Prep TLC) 
and Flash Column Chromotography. Prep TLC was performed on pre-coated plates with silica 
gel coated 1000-µm thick from Analchem. Flash column chromatography was performed under a 
pressure of 4 psi with silica gel 70-230 mesh, 60 Å from Sigma-Aldrich®.   
All synthesized compounds were characterized by Nuclear Magnetic Resonance (NMR) 
Spectroscopy, High-Resolution/Low-Resolution Mass Spectrometry (HR/LRMS), Gas 
Chromatography-Mass Spectrometry (GC-MS) and Polarimetry when applicable. All 1H- and 
13C-NMR data were recorded on a Bruker 300 Fourier transform spectrometer at 300 MHz (1H-
NMR) or 75 MHz (13C-NMR). Samples of interest were diluted in acetone-d6, chloroform-d 
(CDCl3) and benzene-d6 (C6D6). Chemical shifts (δ) were reported in parts per million (ppm) 
relative to tetramethylsilane (TMS), while all coupling constants were reported in Hz. HRMS 
and LRMS were performed on a 70-VSE or Q-Tof Ultima mass spectrometer at the University of 
Illinois at Urbana-Champaign Mass Spectrometry Facility. GC-MS results were abstracted from 
an HP 5890 Series II Plus gas chromatograph obtained using a crosslinked 5% diphenyl-95% 
dimethylsiloxane column from Hewlett Packard, and an HP 5972 electrical ionization mass 
detector. Polarimetry was performed on an Autopol® II Automatic Polarimeter.  
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PANC-1 cells were obtained from American Type Culture Collection (ATCC). Materials 
related to cell culture and cytotoxicity assays were purchased from Sigma-Aldrich®, BD Falcon 
BD Falcon®, BD Syringe, VWR®, Rainin, Corning, Celltreat®, Pall® Corporation and Cellgro®. 
Cell counting kit was purchased from Dojindo Molecular Technologies. The cell incubator was a 
product of Sheldon Manufacturing Inc. The microplate reader was a SpectraMax® M3 from 
Molecular Devices. 
Synthesis of (R)-1,2-dihydronaphthalen-1-ol ((R)-33)19,30 
 
Trial 1. (100 mg test reaction) 
Pd[(S)-binap]-Cl2 (26.5 mg, 0.0331 mmol) and zinc powder (251.9 mg, 3.85 mmol) were 
added to an oven-dried round-bottom flask. The system was evacuated and purged with nitrogen 
gas three times. Anhydrous toluene (2 mL) was added to the flask via syringe and the mixture 
was stirred at room temperature under nitrogen for 25 min. Valproic acid (0.32 mL, 2.00 mmol) 
was added to the flask via syringe and the reaction mixture was stirred at room temperature 
under nitrogen for 1 h. Within 7 min following the addition of valproic acid, the reaction mixture 
transitioned from yellow to orange, to red, and finally reached a dark wine color. 7-
oxabenzonorbornadiene (32, 98.4 mg, 0.683 mmol) dissolved in anhydrous toluene (1 mL) was 
added to the reaction mixture, which was allowed to stir under nitrogen at room temperature for 
2 hours. Reaction progress was monitored by TLC (4:1 hexanes:ethyl acetate). The solution was 
stirred in air for an additional 15 minutes, filtered through silica gel, the filter pad washed with 
OH
(R)-33
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2% (v/v) MeOH in CH2Cl2 and the mixture was concentrated in vacuo. The filtrate was diluted 
with CH2Cl2 and extracted with saturated sodium bicarbonate three times to remove excess 
valproic acid. The aqueous layers were combined and extracted once with dichloromethane. The 
organic layers were combined and dried over sodium sulfate. The dried organic fraction was then 
filtered and concentrated in vacuo. The crude mixture was purified via Prep TLC (4:1 
hexanes:ethyl acetate). The desired band (bottom band) was isolated, washed with 100 mL 2% 
(v/v) MeOH in CH2Cl2 and concentrated in vacuo. Further extraction with sodium bicarbonate, 
as well as purification via Prep TLC (4:1 hexanes:ethyl acetate) were performed to minimize 
residual valproic acid. The desired product (R)-33 (17.5 mg) was isolated in 18% yield. TLC Rf 
= 0.24 on silica gel (hexanes:ethyl acetate = 4:1). The absolute configuration was assigned by 
comparison of the optical rotation with the value reported for (S)-33.19 [α]D25 = +42.9° (c = 1.5, 
CHCl3). 1H-NMR (300 MHz, acetone-d6): δ 2.43 (m, 2H), 4.31 (d, J = 5.7 Hz, 1H), 4.84 (m, 
1H), 5.99 (m, 1H), 6.52 (d, J = 9.6 Hz, 1H), 7.10 (dd, J = 5.1 Hz, 3.3Hz, 1H), 7.20 (m, 2H), 7.48 
(m, 1H); 13C-NMR (75 MHz, acetone-d6): δ 34.1, 68.2, 127.1, 127.2, 127.3, 127.5, 128.3, 128.4, 
134.5, 139.7. HRMS (EI) Calc’d for C10H10O: 146.0732; found 146.0731. 
Trial 2. (500 mg scale-up reaction) 
Pd[(S)-binap]-Cl2 (127 mg, 0.159 mmol) and zinc powder (1.1919 g, 18.2 mmol) were 
added to an oven-dried round-bottom flask. The system was evacuated and purged with nitrogen 
gas three times. Anhydrous toluene (13 mL) was added to the flask via syringe and the mixture 
was stirred at room temperature under nitrogen for 25 min. Valproic acid (1.61 mL, 10.0 mmol) 
was added to the flask via syringe and the reaction mixture was stirred at room temperature 
under nitrogen for 1 h. The reaction mixture underwent expected color changes as in trial 1. 7-
oxabenzonorbornadiene (32, 493.7 mg, 3.42 mmol) dissolved in anhydrous toluene (6 mL) was 
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added to the reaction mixture, which was allowed to stir under nitrogen at room temperature for 
2 hours. Reaction progress was monitored by TLC (4:1 hexanes:ethyl acetate). The solution was 
stirred in air for an additional 15 minutes, filtered through silica gel, the filter pad washed with 
2% (v/v) MeOH in CH2Cl2 and the mixture was concentrated in vacuo. The filtrate was diluted 
with CH2Cl2 and extracted with saturated sodium bicarbonate three times to remove excess 
valproic acid. The aqueous layers were combined and extracted once with dichloromethane. The 
organic layers were combined and dried over sodium sulfate. The dried organic fraction was then 
filtered and concentrated in vacuo. The residue was purified via flash column chromatography 
with eluents starting as 100% hexanes and gradually increasing in polarity to 4:1 hexanes:ethyl 
acetate. Further extraction with sodium bicarbonate, as well as purification via Prep TLC (4:1 
hexanes:ethyl acetate) were needed to minimize residual valproic acid. The desired product (R)-
33 (241.5 mg) was isolated in 48% yield. TLC Rf = 0.24 on silica gel (hexanes:ethyl acetate = 
4:1). The absolute configuration was assigned by comparison of the optical rotation with the 
value reported for (S)-33.19 [α]D25 = +28.0° (c = 1.5, CHCl3). Characterization data see trial 1.   
Synthesis of (R)-tert-butyl((1,2-dihydronaphthalen-1-yl)oxy)diphenylsilane ((R)-34)19 
 
(R)-33 (93.5 mg, 0.640 mmol), imidazole (121.5 mg, 1.78 mmol), and DMAP (6.3 mg, 
0.052 mmol) were dissolved in 3.5 mL of anhydrous CH2Cl2 in an oven-dried round-bottom 
flask. TBDPSCl (185 µL, 0.711 mmol) dissolved in 3.5 mL of anhydrous CH2Cl2 was added to 
the reaction flask via syringe. The reaction was allowed to stir at room temperature under 
OTBDPS
(R)-34
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nitrogen. Reaction progress was monitored by TLC (4:1 hexanes:ethyl acetate). No precipitation 
was observed, which was concerning because immediate precipitation was formed in the 
synthesis of (S)-34.19 After 22 h, it was realized that the TBDPSCl purchased was a 1 M solution 
instead of pure TBDPSCl. Therefore, the calculation for the amount of TBDPSCl needed was 
corrected and another 1.1 equivalent of TBDPSCl (0.704 mL, 0.640 mmol) was added to the 
reaction, upon which immediate white precipitate was observed. The reaction was let stir for 
another 30 h. The solvent was removed in vacuo and diethyl ether was added to dilute the 
residue. The precipitate was filtered and washed with diethyl ether. The filtrate was concentrated 
in vacuo and purified via Prep TLC (4:1 hexanes:ethyl acetate). The desired band (top band) was 
isolated, washed with 100 mL 2% (v/v) MeOH in CH2Cl2 and concentrated in vacuo. The 
desired product (R)-34 (157.7 mg) was isolated in 64% yield. TLC Rf = 0.77 on silica gel 
(hexanes:ethyl acetate = 4:1). The absolute configuration was compared to the optical rotation of 
(S)-34.19 [α]D25 = +76.1° (c = 1.5, CHCl3). 1H-NMR (300 MHz, CDCl3): δ 1.08 (s, 9H), 2.15 (m, 
1H), 2.40 (m, 1H), 4.95 (dd, J = 9.5 Hz, 6.1 Hz, 1H), 5.82 (m, 1H), 6.43 (d, J = 9.6 Hz, 1H), 7.24 
(m, 10H), 7.62 (d, J = 7.5 Hz, 2H), 7.73 (d, J = 7.2 Hz, 2H). 13C-NMR (75 MHz, CDCl3): δ 19.3, 
26.9, 32.8, 69.9, 126.2, 127.5, 127.6, 129.3, 129.5, 129.8, 130.0, 133.4 133.7, 134.3, 134.8, 
135.2, 135.6, 136.1, 137.5. HRMS (EI) Calc’d for C26H28OSi: 384.1909; found 384.1905. 
Preparation of tert-butyl((1,2-dihydronaphthalen-1-yl)oxy)diphenylsilane (34) 
 
(R)-34 (8 mg, 0.0208 mmol) and (S)-34 (8 mg, 0.0208 mmol) were transferred and 
combined in acetone and then concentrated in vacuo. The desired racemic mixture 34 (15.8 mg, 
OTBDPS
34
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0.0411 mmol) was obtained in 99% yield. TLC Rf = 0.80 on silica gel (hexanes:ethyl acetate = 
4:1). [α]D25 = 0° (c = 1.5, CHCl3). Charaterization data see (R)-34. 
Synthesis of tert-butyldiphenylsilanol (55)45 
 
Trial 1.  
Potassium hydroxide (KOH, 48.47 mg, 0.864 mmol), deionized water (260 µL) and 
methanol (MeOH, 60 µL) were added to a 10 mL round bottom flask, sealed with a rubber 
septum with a needle for the potential production of HCl gas. The reaction flask was immersed 
in an ice bath at 5 °C. In a separate vial, 160 µL (0.615 mmol) of tert-butylchlorodiphenylsilane 
(54) were added dropwise via syringe to the reaction flask. The mixture was let stir at 5 °C for 10 
min. Reaction progress was monitored by TLC (4:1 hexanes:ethyl acetate). Two spots were 
observed for the starting material 54, resulting in a suspicion of contamination. Thus, the 
reaction was terminated and stored in the freezer for future analysis.   
Trial 2.  
KOH (57.10 mg, 1.018 mmol), deionized water (260 µL) and MeOH (80 µL) were added 
to a 10-mL round bottom flask, sealed with a rubber septum with a needle for the potential 
production of HCl gas. The reaction flask was immersed in an ice bath at 5 °C. In a separate vial, 
170 µL (0.654 mmol) of tert-butylchlorodiphenylsilane (54) were dissolved in 520 µL of diethyl 
ether. The solution was added dropwise via syringe to the reaction flask. The mixture was let stir 
at 5 °C and slowly warmed up to room temperature, and reaction from trial 1 was resumed under 
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2 h, both reactions were treated with an additional equivalent of KOH (57.10 mg, 1.018 mmol) 
and deionized water (260 µL), and let stir for 26 h in total. Both reaction mixtures were 
combined and extracted three times with diethyl ether. The organic layers were combined and 
dried over sodium sulfate. The dried organic fraction was then filtered and concentrated in 
vacuo. The crude mixture was purified via Prep TLC (4:1 hexanes:ethyl acetate). The desired 
band (bottom band) was isolated, washed with 100 mL 2% (v/v) MeOH in CH2Cl2 and 
concentrated in vacuo. TLC Rf = 0.78 on silica gel (hexanes:ethyl acetate = 4:1). 1H-NMR (300 
MHz, acetone-d6): δ 1.03 (s, 9H), 5.54 (s, 1H), 7.40 (m, 3H), 7.80 (m, 2H). 13C-NMR (75 MHz, 
CDCl3): δ 19.3, 26.5, 127.5, 129.6, 134.6, 134.9. HRMS (EI) Calc’d for C16H20OSi: 256.1283; 
found 256.1295. 
2D-TLC for Decomposition Check of 54.  
 A small amount of a solution of 54 in acetone was spotted on a TLC plate, which was 
placed and let develop in a chamber with a mobile phase of 4:1 hexanes:ethyl acetate. The TLC 
plate was removed from the chamber when the mobile phase was about 1 cm below the top edge 
of the plate. The migrated spots were marked under a UV lamp. The plate was then rotated 90° 
and placed back into the chamber, until the mobile phase reached the desired position. The 
positions of updated spots were marked under a UV lamp.  
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(S)-33 (46.6 mg, 0.319 mmol) was dissolved in 0.3 mL of anhydrous CH2Cl2 in an oven-
dried round-bottom flask. The solution was let stir at 0 °C under nitrogen. Triethylamine (50 µL, 
0.711 mmol), DMAP (3.6 mg, 0.0295 mmol) and trityl chloride (100 mg, 0.359 mmol) were 
added to the reaction flask. The reaction mixture became orange brown after 1 h of stirring and 
was allowed to stir at room temperature under nitrogen for 24 h. Reaction progress was 
monitored by TLC (4:1 hexanes:ethyl acetate and 9:1 hexanes:ethyl acetate). The mixture was 
diluted with CH2Cl2 and deionized water. The organic layer was washed with water and brine 
three times each. The organic layer was dried over sodium sulfate and filtered. The filtrate was 
concentrated in vacuo and purified via Prep TLC (4:1 hexanes:ethyl acetate and 9:1 
hexanes:ethyl acetate). The desired band was isolated and the starting material band was 
retrieved. Both bands were washed with 100 mL 2% (v/v) MeOH in CH2Cl2 and concentrated in 
vacuo. The desired product (S)-60 (50.7 mg) was isolated in 41% yield. 22.8 mg of starting 
material (S)-33 was recovered from Prep TLC purification. TLC Rf = 0.78 on silica gel 
(hexanes:ethyl acetate = 4:1) and Rf = 0.62 on silica gel (hexanes:ethyl acetate = 9:1) [α]D25 = -
16.6° (c = 1.5, CHCl3). 1H-NMR (300 MHz, CDCl3): δ 1.69 (m, 2H), 4.54 (t, J = 5.6 Hz, 7.3 Hz, 
1H), 5.75 (m, 1H), 6.48 (d, J = 9.5 Hz, 1H), 7.06 (d, J = 7.1 Hz, 1H), 7.30 (m, 11H), 7.52 (d, J = 
7.4 Hz, 7H); 13C-NMR (75 MHz, CDCl3): δ 30.4, 70.6, 87.5, 126.3, 126.8, 127.3, 127.5, 127.8, 
128,1, 128.8, 129.4, 134.6, 136.8. HRMS (ESI) Calc’d for C29H24ONa: 411.1725; found 
411.1734. 
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Synthesis of tert-butyldimethylsilanol (75)45 
 
KOH (50.65 mg, 0.904 mmol), deionized water (500 µL) and MeOH (160 µL) were added to a 
10-mL round bottom flask, sealed with a rubber septum with a needle for the potential 
production of HCl gas. The reaction flask was immersed in an ice bath at 5 °C. In a separate vial, 
216.0 mg (1.64 mmol) of tert-butylchlorodimethylsilane (TBDMSCl) were dissolved in 1 mL of 
diethyl ether. The solution was added dropwise via syringe to the reaction flask. The mixture was 
let stir at 5 °C and slowly warmed up to room temperature. Reaction was let stir for 24 h.  
Reaction progress was not monitored, since neither reactant nor product was UV-active. The 
reaction mixture were combined and extracted three times with dichloromethane. The organic 
layers were combined and dried over sodium sulfate. The dried organic fraction was then filtered 
and concentrated in vacuo. The desired product was obtained in 33% yield. 1H-NMR (300 MHz, 
CDCl3): δ 0.00 (s, 6H), 0.83 (s, 9H), 2.91 (s, 1H). 13C-NMR (75 MHz, CDCl3): δ -4.23, 17.0, 
24.9. GC-MS: 4.30 min, m/z = 132 (0.02, M), 75 (100, M-t-Bu). 
Preparation of complete Dulbecco Modified Eagle’s Medium (DMEM) 
One bottle of DMEM powder (Sigma-Aldrich) was dissolved in 800 mL of HPLC grade 
water. Sodium bicarbonate solution (49.1 mL) and 10 mL of 100x antibiotic-antifungal solution 
were added to the mixture. The volume was brought to 900 mL and the solution was adjusted to 
a pH between 7-7.4. Heat-inactivated fetal bovine serum (FBS, 100 mL) were added to the 
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Preparation of Nutrient-Deprived Medium (NDM), Nutrient-Rich Medium (NRM) and 
Media 1-611 
For all medium conditions, the following electrolytes and vitamin solution were added in 
concentrations as follows: CaCl2 (2H2O), 265 mg/L; Fe(NO3)(9H2O), 0.1 mg/L; KCl, 400 mg/L; 
MgSO4(7H2O), 200 mg/L; NaCl, 6400 mg/L; NaHCO3, 700 mg/L; NaH2PO4, 125 mg/L; phenol 
red, 15 mg/L; 25 mM (5.958 g/L) HEPES buffer (pH 7.4); and MEM vitamin solution (1x/L) 
(Life Technologies, Inc., Rockville, MD), which completed the preparation of the NDM. For 
NRM, additional nutrients were supplement at concentrations as follows: D-glucose, 1000mg/L; 
L-glutamine, 2mM; MEM amino acids solution and MEM nonessential amino acids solution 
(Life Technologies, Inc.), 20 mL and 10 mL respectively for 1-L medium; FBS, 100 mL for 1-L 
medium.  For media 1-6 (Table 3), corresponding combinations of nutrients were added at 
concentrations identical to those in NRM.   
Tumor Cell Culture Procedures 
To a cell-containing T-75 culture flask, 2-5 mL aliquot of filtered trypsin-EDTA was 
added to detach the cells after the aspiration of DMEM and a PBS wash. The trypsin-containing 
flask was placed in the incubator (37 °C and 5% CO2) for 2-3 minutes and then monitored under 
a microscope with a 10x amplification. Detached cells were transferred to a 15 mL centrifuge 
tube and pelleted for 3 minutes at 1000 rpm. The supernatant of the resulting content was 
aspirated. The cell pellet was re-suspended thoroughly in the complete DMEM and transferred to 
an appropriately-labeled T-75 flask with additional DMEM to reach a final volume of 25 mL.  
General Procedures of Cytotoxicity Assays 
In vitro cytotoxicity assay: Pancreatic cancer cells (PANC-1, BxPc-3 or Capan-2), 
ranging from passage number 40-52 for PANC-1 (passage numbers not available for BxPc-3 and 
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Capan-2), were seeded in 96-well plates at a density of 23,000 cells per well and incubated in a 
fresh Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich) at 37 °C, 5% CO2 for 24 h. 
After rinsing with PBS, cells were subjected to the addition of NRM, NDM, or media 1-6. 
Serially diluted solutions of synthesized compounds (5.5% v/v DMSO in NDM) were added to 
the cells up to a series of concentrations of 100 µM, 50 µM, 25 µM, 12.5 µM and 6.25 µM, 
followed by a 24 h incubation at 37 °C, 5% CO2. Cell morphology was monitored under an 
inverted microscope. Cytotoxicity was assessed on PBS washed cells by the addition of fresh 
DMEM containing 10% WST-8 cell counting reagent (Dojindo). Following a 3 h incubation at 
37 °C, 5% CO2, absorbance values were measured with a plate reader at 450 nm, and cell 
viability was calculated using the equation:  
% cell viability = [{Abstest sample –  Absblank}/{Abscontrol – Absblank}]*100. 
Cytotoxicity Assays of Spiroxin A Derivatives against PANC-1  
A replicate experiment for each of the four synthetic intermediates (S)-33, (S)-34, (S)-36 
and (S)-37 was performed following the general cytotoxicity assay procedures in NRM and 
NDM, in order to validate the preliminary data obtained from a former member of our 
laboratory.22  
Two to three replicate experiments were conducted for each of the following compounds: 
32, (R)-33, (R)-34, 34, 55, (S)-60 and 75, following the same assay procedures mentioned above.  
Cytotoxicity Assays of 50 against PANC-1  
A total of 6 assays were performed following the general cytotoxicity assay procedures.47 
Each assay contained NRM, NDM and two of the six medium conditions in Table 3. Two 
replicate experiments were conducted for each medium condition in Table 3, and similar results 
were obtained.  
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Cytotoxicity Assays of 50 against BxPc-3 and Capan-2  
Two replicate assays were performed48 following the general cytotoxicity assay 
procedures. Each assay tested the cytotoxicity of 50 against both cell lines in NRM and NDM. 
Similar results were obtained.  
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